Source: Virtual Congress 2020 – Bronchiectasis: epidemiology, endotyping and therapy
Disease area: Airway diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
M. Loebinger (London, United Kingdom), E. Polverino (Barcelona, Spain), F. Blasi (Milan, Italy), S. Elborn (Belfast, United Kingdom), J. Chalmers (Scotland, United Kingdom), H. Tiddens (Rotterdam, Netherlands), H. Goossens (Antwerp, Belgium), M. Tunney (Belfast, United Kingdom), F. Ringshausen (Hannover, Germany), A. Hill (Edinburgh, United Kingdom), R. Pathan (Hyderabad, India), G. Angyalosi (Basel, Switzerland), C. Haworth (Cambridge, United Kingdom). Efficacy of inhaled dry powder tobramycin (TOBI Podhaler) in P. aeruginosa infected patients with bronchiectasis - iBEST study. 4105

Member's Comments

No comment yet.

Related content which might interest you: Efficacy and safety of TOBI Podhaler in Pseudomonas aeruginosa-infected bronchiectasis patients: iBEST study Source: Eur Respir J, 57 (1) 2001451; 10.1183/13993003.01451-2020 Year: 2021 The effect of tobramycin nebulised solution in COPD patients with Pseudomonas aeruginosa in sputum (preliminary report) Source: Eur Respir J 2004; 24: Suppl. 48, 409s Year: 2004 Tobramycin by aerosol (Toby®) eradicates Pseudomonas aeruginosa resistant to Tobramycin i.v. in patients with infected bronchiectasis Source: Eur Respir J 2001; 18: Suppl. 33, 542s Year: 2001 Eradication treatment in Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) on patients with pseudomonas aeruginosa Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections Year: 2017 A randomised placebo-controlled dose finding study of tobramycin inhalation powder (TIP) in patients with bronchiectasis (BE) and pulmonary P. aeruginosa Pa) infection (iBEST-1) Source: International Congress 2018 – Improving the quality of life of patients with bronchiectasis Year: 2018 Baseline profiles of subjects randomised in RESPIRE 2 trial of ciprofloxacin dry powder for inhalation (DPI) in non-CF bronchiectasis (NCFB) by pathogen and prior exacerbation rate Source: International Congress 2016 – Possible phenotypes of bronchiectasis and exacerbations Year: 2016 Effectiveness and adherence to treatment with nebulized colistimethate sodium (Promixin®) in non-cystic fibrosis bronchiectasis colonized by pseudomonas aeruginosa (PsA) Source: International Congress 2015 – Bronchiectasis and NTM infections: clinical aspects and research outlook Year: 2015 Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis Year: 2011 Efficacy of ciprofloxacin against resistant mucoid or non-mucoid P. aeruginosa isolated from non-cystic fibrosis bronchiectasis (NCFB) patients considering lung pharmacokinetics after ciprofloxacin DPI treatment Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis: a phase II randomised study Source: Eur Respir J 2013; 41: 1107-1115 Year: 2013 Efficacy and safety of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis Year: 2011 Safety and pharmacokinetics of two dose strengths of ciprofloxacin dry powder for inhalation (DPI) in patients with moderate to severe COPD Source: Annual Congress 2012 - Hot topics in respiratory infections Year: 2012 Reduction of the cost associated with exacerbations after treatment with nebulized sodium colistimethate (Promixin®) in patients with bronchiectasis (BQ) and chronic bronchial infection (CBI) with Pseudomonas aeruginosa (PsA). Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections Year: 2017 A placebo-controlled study of liposomal amikacin for inhalation nebulized once daily in the treatment of bronchiectasis patients with chronic pseudomonas aeruginosa lung infection Source: Annual Congress 2009 - Respiratory infection caused by Pseudomonas aeruginosa Year: 2009 Non-CF bronchiectasis: nebulised colistimethate sodium improves symptoms and bacterial load in sputum of patients with pseudomonas aeruginosa Source: Annual Congress 2008 - Microbiology and treatment of bronchiectasis and exacerbations of COPD Year: 2008 The effect of nebulised colistimethate sodium on non-CF bronchiectasis with pseudomonas aeruginosa (preliminary report) Source: Eur Respir J 2007; 30: Suppl. 51, 439s Year: 2007 Non CF bronchiectasis: The effect of inhaled antibiotics (tobramycin and colistin) in patients with pseudomonas aeruginosa Source: International Congress 2014 – Interventions and other therapeutic approaches in respiratory infections Year: 2014 A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis Source: Eur Respir J 2002; 20: 658-664 Year: 2002 Distribution of nebulised gentamicin in patients with bronchiectasis Source: Eur Respir J 2004; 24: Suppl. 48, 640s Year: 2004 Highly concentrated aerosolized tobramycin in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection Source: Eur Respir J 2005; 26: Suppl. 49, 620s Year: 2005